From the Saha Cardiovascular Research Center (C.-H.W., C.W., D.A.H., J.J.M., A.D., H.S.L.), University of Kentucky, Lexington.
Department of Pharmacology and Nutritional Sciences (C.-H.W., L.A.C., A.D., H.S.L.), University of Kentucky, Lexington.
Arterioscler Thromb Vasc Biol. 2020 Sep;40(9):2108-2113. doi: 10.1161/ATVBAHA.120.314048. Epub 2020 Jul 9.
Renin cleavage of angiotensinogen has species specificity. As the residues at positions 11 and 12 are different between human angiotensinogen and mouse angiotensinogen, we determined whether these 2 residues in angiotensinogen affect renin cleavage and angiotensin II-mediated blood pressure regulation and atherosclerosis using an adenoassociated viral approach for manipulating angiotensinogen in vivo. Approach and Results: Hepatocyte-specific angiotensinogen deficient (hepAGT) mice in an LDL receptor-deficient background were infected with adenoassociated virals containing a null insert, human angiotensinogen, or mouse angiotensinogen expressing the same residues of the human protein at positions 11 and 12 (mouse angiotensinogen [L11V;Y12I]). Expression of human angiotensinogen in hepAGT mice led to high plasma human angiotensinogen concentrations without changes in plasma endogenous mouse angiotensinogen, plasma renin concentrations, blood pressure, or atherosclerosis. This is consistent with human angiotensinogen not being cleaved by mouse renin. To determine whether the residues at positions 11 and 12 in human angiotensinogen lead to the inability of mouse renin to cleave human angiotensinogen, hepAGT mice were injected with adenoassociated viral vector encoding mouse angiotensinogen (L11V;Y12I). Expression of mouse angiotensinogen (L11V;Y12I) in hepAGT mice resulted in increased plasma mouse angiotensinogen concentrations, reduced renin concentrations, and increased renal AngII concentrations that were comparable to their concentrations in hepAGT mice. This mouse angiotensinogen variant increased blood pressure and atherosclerosis in hepAGT mice to the magnitude of hepAGT mice.
Replacement of L11 and Y12 to V11 and I12, respectively, in mouse angiotensinogen does not affect renin cleavage, blood pressure, and atherosclerosis in LDL receptor-deficient mice.
肾素对血管紧张素原的裂解具有物种特异性。由于人血管紧张素原和鼠血管紧张素原在第 11 位和第 12 位的残基不同,我们通过腺相关病毒(adenoassociated viral,AAV)在体内操作血管紧张素原的方法,确定血管紧张素原中的这 2 个残基是否影响肾素的裂解以及血管紧张素 II 介导的血压调节和动脉粥样硬化。
在 LDL 受体缺陷背景下,肝细胞特异性血管紧张素原缺乏(hepAGT)小鼠感染含有空插入、人血管紧张素原或表达人蛋白第 11 位和第 12 位相同残基(鼠血管紧张素原[L11V;Y12I])的鼠血管紧张素原的腺相关病毒。人血管紧张素原在 hepAGT 小鼠中的表达导致人血浆血管紧张素原浓度升高,而不改变血浆内源性鼠血管紧张素原、血浆肾素浓度、血压或动脉粥样硬化。这与人肾素不能裂解人血管紧张素原一致。为了确定人血管紧张素原第 11 位和第 12 位的残基是否导致鼠肾素不能裂解人血管紧张素原,hepAGT 小鼠注射了编码鼠血管紧张素原(L11V;Y12I)的腺相关病毒载体。在 hepAGT 小鼠中表达鼠血管紧张素原(L11V;Y12I)导致血浆鼠血管紧张素原浓度升高、肾素浓度降低和肾 AngII 浓度增加,与 hepAGT 小鼠中的浓度相当。这种鼠血管紧张素原变异增加了 hepAGT 小鼠的血压和动脉粥样硬化程度,与 hepAGT 小鼠相当。
分别将鼠血管紧张素原中的 L11 和 Y12 替换为 V11 和 I12,不影响 LDL 受体缺陷小鼠中的肾素裂解、血压和动脉粥样硬化。